ArticleThe Lancet regional health. Europe2025

Dose-dense anthracycline- and taxane-based chemotherapy remains the preferred treatment for selected patients with high-risk early breast cancer.

Matteo Lambertini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.